Market Cap 15.44B
Revenue (ttm) 2.11B
Net Income (ttm) 404.39M
EPS (ttm) N/A
PE Ratio 38.10
Forward PE 36.84
Profit Margin 19.17%
Debt to Equity Ratio 0.00
Volume 353,500
Avg Vol 317,204
Day's Range N/A - N/A
Shares Out 28.17M
Stochastic %K 18%
Beta 1.43
Analysts Hold
Price Target $557.27

Company Profile

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical moni...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 513 579 9911
Fax: 513 579 0444
Address:
5375 Medpace Way, Cincinnati, United States
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 2:09 AM
Actionable Trade Alert for $MEDP: Market Context: $MEDP is currently trading at $544.77, showing a bearish sentiment with an RSI of 31.24, indicating potential oversold conditions. The price is below both the 30-day MA of 591.6 and the 50-day MA of 564.36, suggesting a downward trend. However, the proximity to the 60-day low of 474.92 presents a potential reversal opportunity. Directional Bias: Despite the bearish indicators, the oversold RSI suggests a possible bounce. The price is near the lower end of its 60-day range, which could attract buyers. Trade Plan: - Suggested Entry: $545 - Stop Loss: $520 (4.6% below entry) - Take Profit Targets: - TP1: $570 (4.4% gain) - TP2: $600 (10.0% gain) - TP3: $640 (17.4% gain) Rationale: The targets are set based on resistance levels and the potential for recovery. The risk-reward ratio is favorable, with TP3 offering over 17% ROI. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Dec. 4 at 7:15 PM
0 · Reply
RonIsWrong
RonIsWrong Dec. 4 at 7:09 PM
$VKTX $MEDP $IQV $XBI Why This FDA Shake-Up Rattled Medpace And Iqvia, But Buoyed Viking Therapeutics Biotech stocks, including Viking Therapeutics (VKTX), jumped Thursday on a report that the Food and Drug Administration will soon require just one pivotal study to clinch approval for new medical products. The news could give drug and device approvals a boost, but hurt clinical research organizations like Medpace Holdings (MEDP) and Iqvia Holdings (IQV). The companies are responsible for organizing and running the clinical studies necessary to win regulatory approvals. https://www.investors.com/news/technology/medical-stocks-biotech-stocks-research-stocks-fda-clinical-trials/?mod=IBD_FV
0 · Reply
CatRocks
CatRocks Dec. 4 at 2:59 PM
$MEDP Back to $458?
0 · Reply
SophiaBreez
SophiaBreez Dec. 4 at 1:50 PM
$MEDP 600$
0 · Reply
Mason121
Mason121 Dec. 2 at 1:59 PM
$MEDP doomed lol
0 · Reply
Mason121
Mason121 Dec. 2 at 1:59 PM
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Dec. 2 at 2:32 AM
0 · Reply
Nyman189
Nyman189 Nov. 30 at 8:40 PM
$MEDP Following a strong Q3 2025, one rating service upgraded MEDP to a “Strong Buy” under the framework of rising earnings estimates — suggesting near-term optimism on profit growth...
0 · Reply
Nyman189
Nyman189 Nov. 30 at 7:37 PM
$MEDP Several recent analyses highlight strong fundamentals: good revenue growth, a robust cash-flow profile, and an expanding pipeline of “net new business awards,” which suggests that demand for Medpace’s clinical-research services remains healthy.
0 · Reply
Latest News on MEDP
6 Healthcare Stocks With Strong Upward Momentum

Nov 18, 2025, 12:59 PM EST - 18 days ago

6 Healthcare Stocks With Strong Upward Momentum

ABVX CAH ELAN GH WGS


Why Medpace Popped 13% This Week

Oct 24, 2025, 1:05 PM EDT - 6 weeks ago

Why Medpace Popped 13% This Week


Medpace Holdings, Inc. (MEDP) Q3 2025 Earnings Call Transcript

Oct 23, 2025, 1:37 PM EDT - 6 weeks ago

Medpace Holdings, Inc. (MEDP) Q3 2025 Earnings Call Transcript


Medpace Holdings' Good Quarter Is Another Sign Biotech Is Back

Oct 23, 2025, 11:15 AM EDT - 6 weeks ago

Medpace Holdings' Good Quarter Is Another Sign Biotech Is Back


Medpace Holdings, Inc. Reports Third Quarter 2025 Results

Oct 22, 2025, 4:15 PM EDT - 6 weeks ago

Medpace Holdings, Inc. Reports Third Quarter 2025 Results


Medpace: Return Of The Mack, With Double-Digit Revenue Growth

Aug 4, 2025, 2:25 AM EDT - 4 months ago

Medpace: Return Of The Mack, With Double-Digit Revenue Growth


Medpace Beats Q2 Revenue Estimates

Jul 22, 2025, 10:01 PM EDT - 4 months ago

Medpace Beats Q2 Revenue Estimates


Medpace Holdings, Inc. (MEDP) Q2 2025 Earnings Call Transcript

Jul 22, 2025, 2:14 PM EDT - 4 months ago

Medpace Holdings, Inc. (MEDP) Q2 2025 Earnings Call Transcript


Top 2 Health Care Stocks You May Want To Dump This Quarter

Jul 22, 2025, 7:02 AM EDT - 4 months ago

Top 2 Health Care Stocks You May Want To Dump This Quarter

RXRX


Medpace Holdings, Inc. Reports Second Quarter 2025 Results

Jul 21, 2025, 4:15 PM EDT - 4 months ago

Medpace Holdings, Inc. Reports Second Quarter 2025 Results


Is Medpace Stock Worth the Hype? Here's What Analysts Think.

May 27, 2025, 7:00 PM EDT - 6 months ago

Is Medpace Stock Worth the Hype? Here's What Analysts Think.


Medpace Holdings, Inc. (MEDP) Q1 2025 Earnings Call Transcript

Apr 22, 2025, 3:42 PM EDT - 8 months ago

Medpace Holdings, Inc. (MEDP) Q1 2025 Earnings Call Transcript


Medpace Holdings, Inc. Reports First Quarter 2025 Results

Apr 21, 2025, 4:15 PM EDT - 8 months ago

Medpace Holdings, Inc. Reports First Quarter 2025 Results


1 Spectacular Growth Stock Down 34% to Buy Hand Over Fist

Apr 5, 2025, 6:58 AM EDT - 8 months ago

1 Spectacular Growth Stock Down 34% to Buy Hand Over Fist


Medpace Holdings: It Might Be Time To Buy In

Apr 4, 2025, 8:14 AM EDT - 8 months ago

Medpace Holdings: It Might Be Time To Buy In


Medpace Holdings, Inc. (MEDP) Q4 2024 Earnings Call Transcript

Feb 11, 2025, 5:40 PM EST - 10 months ago

Medpace Holdings, Inc. (MEDP) Q4 2024 Earnings Call Transcript


MoneyShow's Best Investment Ideas For 2025: Part 6

Jan 24, 2025, 2:35 PM EST - 11 months ago

MoneyShow's Best Investment Ideas For 2025: Part 6

ALLY FTI OS PTON UAMY VRT


PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 2:09 AM
Actionable Trade Alert for $MEDP: Market Context: $MEDP is currently trading at $544.77, showing a bearish sentiment with an RSI of 31.24, indicating potential oversold conditions. The price is below both the 30-day MA of 591.6 and the 50-day MA of 564.36, suggesting a downward trend. However, the proximity to the 60-day low of 474.92 presents a potential reversal opportunity. Directional Bias: Despite the bearish indicators, the oversold RSI suggests a possible bounce. The price is near the lower end of its 60-day range, which could attract buyers. Trade Plan: - Suggested Entry: $545 - Stop Loss: $520 (4.6% below entry) - Take Profit Targets: - TP1: $570 (4.4% gain) - TP2: $600 (10.0% gain) - TP3: $640 (17.4% gain) Rationale: The targets are set based on resistance levels and the potential for recovery. The risk-reward ratio is favorable, with TP3 offering over 17% ROI. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Dec. 4 at 7:15 PM
0 · Reply
RonIsWrong
RonIsWrong Dec. 4 at 7:09 PM
$VKTX $MEDP $IQV $XBI Why This FDA Shake-Up Rattled Medpace And Iqvia, But Buoyed Viking Therapeutics Biotech stocks, including Viking Therapeutics (VKTX), jumped Thursday on a report that the Food and Drug Administration will soon require just one pivotal study to clinch approval for new medical products. The news could give drug and device approvals a boost, but hurt clinical research organizations like Medpace Holdings (MEDP) and Iqvia Holdings (IQV). The companies are responsible for organizing and running the clinical studies necessary to win regulatory approvals. https://www.investors.com/news/technology/medical-stocks-biotech-stocks-research-stocks-fda-clinical-trials/?mod=IBD_FV
0 · Reply
CatRocks
CatRocks Dec. 4 at 2:59 PM
$MEDP Back to $458?
0 · Reply
SophiaBreez
SophiaBreez Dec. 4 at 1:50 PM
$MEDP 600$
0 · Reply
Mason121
Mason121 Dec. 2 at 1:59 PM
$MEDP doomed lol
0 · Reply
Mason121
Mason121 Dec. 2 at 1:59 PM
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Dec. 2 at 2:32 AM
0 · Reply
Nyman189
Nyman189 Nov. 30 at 8:40 PM
$MEDP Following a strong Q3 2025, one rating service upgraded MEDP to a “Strong Buy” under the framework of rising earnings estimates — suggesting near-term optimism on profit growth...
0 · Reply
Nyman189
Nyman189 Nov. 30 at 7:37 PM
$MEDP Several recent analyses highlight strong fundamentals: good revenue growth, a robust cash-flow profile, and an expanding pipeline of “net new business awards,” which suggests that demand for Medpace’s clinical-research services remains healthy.
0 · Reply
Nyman189
Nyman189 Nov. 30 at 7:36 PM
$MEDP Up 100% almost long term nice
0 · Reply
Nyman189
Nyman189 Nov. 30 at 7:35 PM
0 · Reply
StockConsultant
StockConsultant Nov. 26 at 2:17 PM
$MEDP Medpace stock, watch for a narrow range breakout at https://stockconsultant.com/?MEDP
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 25 at 8:17 PM
0 · Reply
MichaelKTrades
MichaelKTrades Nov. 23 at 6:39 PM
A few biotech/medical names holding up with constructive price charts. $MEDP $PTGX $INCY (Pullback buy set up)
0 · Reply
WAJeff
WAJeff Nov. 23 at 6:00 PM
$MEDP Not pulling the trigger here was a total idiot moment. 85% since July 14 callout.
1 · Reply
inspector_gadget86
inspector_gadget86 Nov. 22 at 3:40 PM
$RTX $MEDP $AAPL have forged bullish tight patterns.
0 · Reply
JarvisFlow
JarvisFlow Nov. 13 at 9:32 AM
BMO Capital has updated their rating for Medpace Hldgs ( $MEDP ) to Market Perform with a price target of 600.
0 · Reply
MichaelKTrades
MichaelKTrades Nov. 12 at 9:09 PM
$MEDP Inside day pivot, good spot to start new position or add from lower Buy 609.15 Stop 594
0 · Reply
MichaelKTrades
MichaelKTrades Nov. 12 at 3:29 PM
$MEDP Inside day tight pivot, ready for multi week base breakout
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 9 at 10:23 PM
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 4 at 11:19 PM
0 · Reply